A ‘slow catastrophe’ unfolds as the golden age of antibiotics comes to an end

http://www.latimes.com/science/sciencenow/la-sci-antibiotic-resistance-20160711-snap-story.html

Rosslyn Maybank

In early April, experts at a military lab outside Washington intensified their search for evidence that a dangerous new biological threat had penetrated the nation’s borders.

They didn’t have to hunt long before they found it.

On May 18, a team working at the Walter Reed Army Institute of Research here had its first look at a sample of the bacterium Escherichia coli, taken from a 49-year-old woman in Pennsylvania. She had a urinary tract infection with a disconcerting knack for surviving the assaults of antibiotic medications. Her sample was one of six from across the country delivered to the lab of microbiologist Patrick McGann.

Within hours, a preliminary analysis deepened concern at the lab. Over the next several days, more sophisticated genetic sleuthing confirmed McGann’s worst fears.

There, in the bacterium’s DNA, was a gene dubbed mcr-1. Its presence made the pathogen impervious to the venerable antibiotic colistin.

Can the government encourage the development of new antibiotics?

http://www.latimes.com/science/sciencenow/la-sci-sn-antibiotic-resistance-government-incentives-20160711-snap-story.html?utm_campaign=KHN%3A+First+Edition&utm_source=hs_email&utm_medium=email&utm_content=31540667&_hsenc=p2ANqtz-8KSOwnDu9wgUrlDN8u_2HnowEpWjJZShjqIFvN-mLC_3gavkn6QZ5XuGYVoKPH71cmkDrEhbc1BXnicLRSAOV4ZkDaTQ&_hsmi=31540667

Antibiotics

It’s been nearly 30 years since scientists have found a new class of antibiotics. But U.S. lawmakers tried to give the drug industry a boost in 2012.

That year, they passed the Food and Drug Administration Safety and Innovation Act. It included provisions — collectively known as Generating Antibiotic Incentives Now, or GAIN — aimed at streamlining the government approval process for new antibiotics. It also boosted financial paybacks to drug companies that develop them.